About this trial
This trial studies how well ixazomib works for patients with Kaposi sarcoma. Ixazomib might stop tumor cells from growing by blocking certain enzymes the cells need. The main goal is to see how well patients respond to this treatment. Researchers will also look at the safety of ixazomib and changes in the virus linked to Kaposi sarcoma.
The trial's ID number is NCT04305691. This is a Phase 2 trial, meaning it looks at how well the treatment works and how safe it is. It is regulated by the FDA and aims to include about 41 participants.
Who can join
Adults aged 18 and older can join. This trial is open to both men and women. Participants must have confirmed Kaposi sarcoma and measurable lesions. They also need to have a documented HIV status. A few health criteria must be met, like certain blood counts and kidney function. The trial team will check who is eligible before enrollment.
Conditions
Kaposi Sarcoma, Skin
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Everyone in the trial will receive ixazomib by mouth on specific days of each month. Treatment will repeat every 28 days for up to 12 cycles, as long as there is no disease progression or unacceptable side effects. If patients respond well, they may continue for another 12 cycles. The study also includes quality-of-life assessments and questionnaires during treatment.
Where
This trial is running at 11 locations in the United States. All of them are currently recruiting.
Abramson Cancer Center at Pennsylvania Hospital
Philadelphia, Pennsylvania
Mount Sinai Hospital
New York, New York
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
Thomas Street Clinic
Houston, Texas
Thomas Street Clinic
Houston, Texas
UC San Diego
San Diego, California
University of Illinois Cancer Center
Chicago, Illinois
University of Miami Miller School of Medicine
Miami, Florida
The first 8 of 11 sites are listed here. The registry record has the full list.